Laura Joszt, MA

AI revolutionizes pharmacy by automating workloads, enhancing patient care, and navigating drug pricing challenges amid evolving federal policies.

ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life while reducing burdens.

The FDA approves Wegovy, the first oral GLP-1 pill, offering a new weight loss solution for those struggling with obesity and overweight.

The FDA approved subcutaneous mosunetuzumab for relapsed follicular lymphoma, providing a more convenient outpatient option.

The editors in chief of AJMC discuss the key managed care research and news from 2025 as the journal celebrated its 30th anniversary.

The integration of AI has the potential to enhance oncology clinical pathways, but there are important judgment calls that must be made before this technology can be fully implemented.

Top articles in 2025 covered advancements in acute myeloid leukemia treatments, including allogeneic CAR T-cell therapy.

Recent political shifts impacting health policy and access to care for millions dominated the news in 2025.

Blinatumomab enhances survival in pediatric B-cell ALL, yet homecare challenges hinder its outpatient delivery.

Financial and social barriers hinder access to specialized care and impact treatment outcomes for adolescents and young adults with leukemia.

Payer and health system leaders convened in Pittsburgh, Pennsylvania, on September 9, 2025, to discuss the interconnected health conditions of cardiovascular-kidney-metabolic (CKM) syndrome.

Pretransplant NPM1 MRD testing significantly predicts relapse risk in acute myeloid leukemia.

Research challenges age cut-offs in AML treatment, advocating for flexible, individualized approaches based on continuous age assessment.

There is an urgent need for equitable care and access to cardiovascular care, said Vallerie McLaughlin, MD; Martha Gulati, MD; and Stephen Nicholls, MBBS, PhD.

The FDA approved ziftomenib for relapsed acute myeloid leukemia with NPM1 mutations, offering hope for high-risk patients.

Tirzepatide's dual mechanism targets GIP and GLP-1, so it provides strong cardiovascular benefits, said Stephen Nicholls, MBBS, PhD, MBA.

New findings reveal sotagliflozin's benefits for patients with heart failure with preserved ejection fraction without diabetes, said Juan Badimon, PhD.

Integrating nephrology and cardiology care for patients with kidney and cardiovascular (CV) risks can be challenging but is possible, said Roy Mathew, MD.

Prioritizing education and shared decision-making can help patients with newly diagnosed heart failure feel less overwhelmed, said Martha Gulati, MD.

Sotatercept can enhance treatment for pulmonary arterial hypertension, even in patients already on conventional therapies, said Vallerie McLaughlin, MD.

The oral PCSK9 inhibitor enlicitide can change cholesterol management with high efficacy and improved adherence, said Ann Marie Navar, MD, PhD.

Experts discuss the evolving landscape of CLL treatment, cellular therapies, and innovative diagnostics shaping patient care and cost-effectiveness in oncology.

Guideline adherence in treating acute lymphoblastic leukemia (ALL) enhances health care resource utilization, especially for adolescent and young adult patients.

Experts at CHEST 2025 highlight rising costs, insurance complexity, and workforce shortages as major barriers to health care access in the US.

Vaccine awareness, safety, and addressing misinformation are all important to improve adherence and public health outcomes, said Kristina Crothers, MD.

The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations.

Elinzanetant offers a promising alternative to hormone therapy for women seeking relief from menopause symptoms, said JoAnn V. Pinkerton, MD.

A novel combination therapy enhances the effectiveness of proteasome inhibitors against acute myeloid leukemia (AML), improving survival rates in preclinical models.

Dedicated COPD respiratory therapists can improve inhaler use, ensure adherence, and bridge care transitions, explained Megan Dulohery Scrodin, MD.

Assessing all available nonhormonal and hormonal therapies for vasomotor symptoms helps empower women to make informed decisions, said Lee Shulman, MD.